mRNA vaccine plus immunotherapy for advanced solid tumors
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial is testing an experimental mRNA vaccine (which targets a protein called circFAM53B-219aa found on tumor cells) combined with an immunotherapy drug (anti-PD-1) to treat advanced cancers that have stopped responding to standard treatments. The goal is to see if this combination is safe and effective for people with solid tumors like lung, breast, melanoma, pancreatic, and colon cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor (such as lung, breast, melanoma, pancreatic, or colon cancer) that has not responded to standard treatment or you can't tolerate standard treatment.
- You are at least 18 years old and are expected to live at least 3 months.
- You have a tumor sample (fresh or stored) that tests positive for a specific marker (circFAM53B-219aa).
- You have a specific HLA type (a tissue type) that can be identified through a blood test.
- You have at least one measurable tumor on scans (RECIST v1.1 criteria).
- Your cancer has not spread to the brain or you have stable brain metastases (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This study tests two experimental mRNA vaccines (mRNA-4106 and mRNA-4200) given either alone or together with other cancer treatments. The goal is to see if they are safe and work against advanced or metastatic solid tumors like melanoma, lung, liver, and colon cancer. Participation requires that you have tried or refused all standard treatments.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This trial tests a new mRNA vaccine that targets a protein called FAP, which is found in many solid tumors. The vaccine aims to help the immune system fight the cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.